Effects of levetiracetam on chronic pain in multiple sclerosis: results of a pilot, randomized, placebo‐controlled study
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Background and purpose: Central neuropathic pain (CNP) is a prevalent and distressing symptom in patients with multiple sclerosis (MS). The anticonvulsant levetiracetam (LEV) has been shown to be efficacious in some types of CNP, but its efficacy in MS‐related CNP has not been confirmed. Methods: To investigate the tolerability and potential effects of LEV against CNP in MS subjects, we performed a single‐center, prospective, randomized, single‐blind, placebo‐controlled study in twenty patients with MS and CNP. Outcomes before and during the 3‐month study were assessed using validated measures of pain, depression, disability and quality of life. Results: The medication was well tolerated and analysis revealed a significant difference between the LEV and placebo arm in all study outcomes related to pain (mean pain intensity score, mean pain difference, percentage of patients with a clinically significant pain reduction). Furthermore, the individual quality of life rating improved in treated patients, showing a significant correlation with pain reduction. Conclusions: These findings suggest that further studies with larger samples of patients be carried out in order to confirm the efficacy of LEV in MS‐related CNP population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Farrar, J. T., Young, J. P., LaMoreaux, L., Werth, J. L., & Poole, M. R. (2001) · Pain · doi:10.1016/s0304-3959(01)00349-9 · Cited by 5,808
The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam
Lynch, B. A., Lambeng, N., Nocka, K., Kensel-Hammes, P., Bajjalieh, S. M., Matagne, A., & Fuks, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308208101 · Cited by 1,610 · cited 1×
“SV2A seems to play a role in the modulation of the exocytosis [40].”
BackgroundRandomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis
Rog, D. J., Nurmikko, T. J., Friede, T., & Young, C. A. (2005) · Neurology · doi:10.1212/01.wnl.0000176753.45410.8b · Cited by 679 · cited 1×
“In this respect, it is noteworthy that only a few randomized clinical trials of treatments have been conducted so far to deal with this issue [11,12].”
Background
Cited by
Levetiracetam Mechanisms of Action: From Molecules to Systems
Contreras-García, I. J., Cárdenas-Rodríguez, N., Romo-Mancillas, A., Bandala, C., Zamudio, S. R., Gómez-Manzo, S., Hernández-Ochoa, B., Mendoza-Torreblanca, J. G., & Pichardo-Macías, L. A. (2022) · Pharmaceuticals · doi:10.3390/ph15040475 · Cited by 131
“reported the beneficial effects of LEV (3000 mg/day for 6 weeks) in the control of central neuropathic pain symptoms in patients with multiple sclerosis (MS) [13,14].”
BackgroundNon-pharmacological interventions for chronic pain in multiple sclerosis
Amatya, B., Young, J., & Khan, F. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012622.pub2 · Cited by 78
Cepeda, M. S., Berlin, J. A., Gao, C. Y., Wiegand, F., & Wada, D. R. (2012) · Pain Medicine · doi:10.1111/j.1526-4637.2012.01340.x · Cited by 71
Mealy, M. A., Kozachik, S. L., & Levy, M. (2019) · Pain Management Nursing · doi:10.1016/j.pmn.2019.03.003 · Cited by 20
Metadata
- Authors
- Rossi, S., Mataluni, G., Codecà, C., Fiore, S., Buttari, F., Musella, A., Castelli, M., Bernardi, G., & Centonze, D.
- Venue
- European Journal of Neurology
- Publisher
- Wiley
- Published
- 2009-02-05
- Volume
- 16
- Issue
- 3
- Pages
- 360-366
- ISSN
- 1351-5101 (ISSN-L)
- 1468-1331
- OpenAlex
- W2008356917
- Cited by
- 75
- References
- 3
- FWCI
- 6.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of levetiracetam on chronic pain in multiple sclerosis: results of a pilot, randomized, placebo‐controlled study. https://app.cochat.ai/papers/10.1111/j.1468-1331.2008.02496.x
- The paper
- Rossi, S., Mataluni, G., Codecà, C., Fiore, S., Buttari, F., Musella, A., Castelli, M., Bernardi, G., & Centonze, D. (2009). Effects of levetiracetam on chronic pain in multiple sclerosis: results of a pilot, randomized, placebo‐controlled study. European Journal of Neurology. https://doi.org/10.1111/j.1468-1331.2008.02496.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.